



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

LYNOZYFIC

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency's update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to **EPAR - Procedural steps taken and scientific information after authorisation (archive)**.

| Application number | Scope | Opinion/ Notification ¹ issued on | Commission Decision Issued ² / amended on | Product Information affected ³ | Summary |
|---------------------|--|--|---|---|---------|
| Variation type IB / | This was an application for a group of | 21/07/2025 | | SmPC, | |

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



| | | | | | |
|--|--|------------|-----|------------------|--|
| EMA/VR/0000273555 | <p>variations.</p> <p>B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological medicinal product in accordance with an approved stability protocol - Accepted</p> <p>B.I.d.1.a Re-test period/storage period - B.I.d.1.a.4 Extension or introduction of a re-test period/storage period supported by real time data - Accepted</p> | | | Labelling and PL | |
| Variation type IA / EMA/VR/0000282354 | <p>This was an application for a group of variations.</p> <p>B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.c Addition of a new specification parameter to the specification with its corresponding test method - Accepted</p> <p>B.II.b.5 Change to in-process tests or limits applied during the manufacture of the finished product - B.II.b.5.b Addition of a new test(s) and limits - Accepted</p> <p>B.II.b.5 Change to in-process tests or limits applied during the manufacture of the finished product - B.II.b.5.b Addition of a</p> | 14/07/2025 | N/A | | |

| | | | | | |
|--|--|------------|-----|--|--|
| | <p>new test(s) and limits - Accepted</p> <p>A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted</p> <p>B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.b Tightening of specification limits - Accepted</p> <p>B.I.a.4 Change to in-process tests or limits applied during the manufacture of the active substance - B.I.a.4.z Other variation - Accepted</p> | | | | |
| Variation type IB / EMA/VR/0000272359 | <p>B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted</p> | 12/06/2025 | N/A | | |